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Abstract
Background: A three-drug regimen (macrolide, ethambutol, and rifampicin) is recommended for the treatment of
Mycobacterium avium complex pulmonary disease (MAC-PD). Although macrolide has proven efficacy, the role of
ethambutol and rifampicin in patients without acquired immune deficiency syndrome is not proven with clinical
studies. We aimed to clarify the roles of ethambutol and rifampicin in the treatment of MAC-PD.
Methods: Patients treated for MAC-PD between March 1st, 2009 and October 31st, 2018 were reviewed
retrospectively. Rates of culture conversion, microbiological cure, treatment failure, and recurrence were compared
according to the maintenance (≥6 months) of ethambutol or rifampicin with macrolide.
Results: Among the 237 patients, 122 (51.5%) maintained ethambutol and rifampicin with macrolide, 58 (24.5%)
maintained ethambutol and macrolide, 32 (13.5%) maintained rifampicin and macrolide, and 25 (10.6%) maintained
macrolide only. Culture conversion was reached for 190/237 (80.2%) patients and microbiological cure was achieved
for 129/177 (72.9%) who completed the treatment. Treatment failure despite ≥12 months of treatment was
observed in 66/204 (32.4%), and recurrence was identified in 16/129 (12.4%) who achieved microbiological cure.
Compared with maintenance of macrolide only, maintenance of ethambutol, rifampicin or both with macrolide
were associated with higher odds of culture conversion [odds ratio (OR), 95% confidence interval (CI): 18.06, 3.67–
88.92; 15.82, 2.38–105.33; and 17.12, 3.93–74.60, respectively]. Higher odds of microbiological cure were associated
with maintenance of both ethambutol and rifampicin with macrolide (OR, 95% CI: 5.74, 1.54–21.42) and macrolide
and ethambutol (OR, 95% CI: 5.12, 1.72–15.24) but not macrolide and rifampicin. Maintenance of both ethambutol
and rifampicin with macrolide was associated with lower odds of treatment failure (OR, 95% CI: 0.09, 0.01–0.53)
compared with macrolide only, while maintenance of one of these with macrolide was not. Maintenance of both
ethambutol and rifampicin or one of these with macrolide did not decrease the probability of recurrence when
compared with macrolide only.
Conclusions: Maintenance (≥6 months) of ethambutol and rifampicin with macrolide was associated with the most
favorable treatment outcomes among patients with MAC-PD. Given the association between ongoing ethambutol
use and microbiological cure, clinicians should maintain ethambutol unless definite adverse events develop.
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Background
The prevalence of nontuberculous mycobacterial (NTM)
pulmonary disease is increasing globally, with the most
common pathogen being Mycobacterium avium com-
plex (MAC) species [1–3]. MAC is a ubiquitous organ-
ism commonly found in water, dirt, and soil but can
cause serious pulmonary diseases in some people. M.
avium and M. intracellulare are the most well-known
pathogens, but other MAC such as M. arosiense, M. bou-
chedurhonense, M. chimaera, M. colombiense, M. mar-
seillense, M. timonense, M. vulneris, and M. yongonense
can also cause pulmonary diseases [4].
Treatment for MAC pulmonary disease (MAC-PD) re-
quires consideration of clinical and/or radiographical de-
terioration and usually comprises a multidrug regimen
including macrolide, ethambutol, and rifampicin, with
varying success [5]. A recent systematic review reported
that the three-drug regimen (macrolide, ethambutol, and
rifampicin) with occasional use of an injectable agent
could cure MAC-PD in 57% of patients [6].
The recommendation of such a combination is based
on previous studies about disseminated MAC disease in
acquired immune deficiency syndrome (AIDS) patients
[7]. The efficacy of macrolide among MAC-PD patients
is well established, but macrolide monotherapy can in-
duce microbiological resistance [8]. Therefore, compan-
ion drugs such as ethambutol or rifampicin are used.
Nevertheless, the individual effectiveness of these two
drugs in patients without AIDS is not proven with clin-
ical studies. Considering the long-term use of medica-
tion and possible adverse events, recognizing the most
efficacious accompanying drug is necessary.
The aim of this study was to elucidate the roles of eth-




Patients aged 19 years or older in whom treatment for
MAC-PD was initiated between March 1st, 2009 and
October 31st, 2018 at Seoul National University Hospital
were included. Diagnosis of MAC-PD was based on the
2007 American Thoracic Society and the Infectious
Diseases Society of America guideline [5] and the 2017
British Thoracic Society guideline [9]. Some patients
were included in our previous reports [10, 11].
The study was conducted in accordance with the
amended Declaration of Helsinki and was approved by the
institutional review board of Seoul National University
Hospital (protocol number: H-1705-017-851). Informed
consent was waived because of the retrospective design of
the study, and the information of each patient was anon-
ymized prior to analyses.
Clinical, microbiological, and radiographic evaluation
Clinical, microbiological, and radiographic information
were collected retrospectively. Cultures were grown in
both solid Ogawa media and the BACTEC MGIT 960
system, and isolated NTM were identified into species
[4]. Identification was performed based on sequence
analysis of the 16S rRNA and rpoB gene using the algo-
rithm described in the Clinical and Laboratory Standards
Institute guidelines MM18-A [12]. Once the NTM was
identified as MAC, a drug susceptibility test for clari-
thromycin was performed. The minimal inhibitory con-
centration (MIC) test was performed at the Korean
Institute of Tuberculosis, and was determined using the
broth microdilution method in accordance with the
Clinical and Laboratory Standards Institute guidelines
[12]. Isolates were considered susceptible if the MIC of
clarithromycin was ≤8 μg/mL, resistant if ≥32 μg/mL,
and intermediate if 16 μg/mL on Mueller–Hinton agar.
Chest computed tomography findings were categorized
as the nodular bronchiectatic form when bilateral bron-
chiectasis and cellular bronchiolitis were mainly present,
and the upper lobe cavitary form when cavities in the
upper lobes were observed [13].
Treatment and follow-up
The treatment regimen was mainly based on the 2007
American Thoracic Society and the Infectious Diseases
Society of America guidelines, but was customized by
the attending physician according to each patient’s
condition [5]. Macrolide was included in every regimen,
and ethambutol and rifampicin were considered as com-
panion drugs. The companion drugs were omitted or
stopped when they were considered clinically inappro-
priate; for example, ethambutol was omitted or stopped
if a patient’s visual acuity deteriorated, and rifampicin
was omitted or stopped when a patient had underlying
liver diseases or newly developed hepatic dysfunction.
Injectable drugs including streptomycin or amikacin
were considered when the MAC-PD was extensive or re-
fractory to other oral agents.
Adverse reactions to medications were recorded by the
physician. Subjective events such as decreased visual
acuity, deteriorating hearing, and nausea were either
self-reported or enquired after by the attending phys-
ician. If patients had symptoms suggesting adverse drug
reactions, they were referred to relevant specialists. The
presumed offending drug was discontinued when clinic-
ally necessary.
Definitions
Maintenance of ethambutol or rifampicin was defined as
more than 6months of use as adopted in a previous
study [14]. Clinical outcomes encompassing culture
conversion, microbiological cure, treatment failure, and
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recurrence were defined among patients with ≥3 follow-
up sputum culture studies. ‘Culture conversion’ was
defined as three consecutive negative sputum culture
results after treatment [15, 16]. The first date of culture-
negative sputum specimen collection was defined as the
day of culture conversion. ‘Microbiological cure’ was de-
fined as the maintenance of negative culture conversion
at the point of treatment completion [16]. ‘Treatment
failure’ was defined as the persistence or re-emergence
of multiple positive cultures for the causative species of
NTM from respiratory samples after ≥12 months of anti-
mycobacterial treatment while the patient was still on
treatment [16]. ‘Recurrence’ was defined as the re-
emergence of causative species of NTM with ≥2 positive
cultures from sputum after achieving a microbiological
cure [15, 16]. The first day of culture-positive sputum
specimen collection was considered as the day of
recurrence.
Statistical analysis
Values were organized as numbers (percentages) for di-
chotomous variables, and medians with interquartile
range (IQR) for continuous variables. Logistic regression
analysis was performed to seek potential predictors for
culture conversion, microbiological cure, and treatment
failure. Odds ratios (ORs) with 95% confidence intervals
(CI) for each candidate predictor were calculated, and
candidates with a p < 0.05 were included in the multivar-
iable models. Kaplan-Meier curves were drawn with log-
rank tests to compare probabilities of initial culture
conversion and recurrence after treatment success, ac-
cording to maintenance of the ethambutol and rifampi-
cin. All statistical analyses and figure drawings were




During the 9-year study period, 331 patients with MAC-
PD initiated treatment. The following patients were ex-
cluded from analysis: 28 patients with short (< 6 months)
duration of treatment at the time point of data collec-
tion, 26 patients who were previously treated for MAC-
PD, 16 patients without ≥3 follow-up cultures, 16
patients with poor compliance to prescriptions (> 1-
month omission of medication during the treatment
period), and 8 patients with clarithromycin-resistant
MAC infection. The remaining 237 patients were in-
cluded for further analysis.
Of the 237 patients treated for MAC-PD, the median
age was 64 years (IQR: 57–73) and 147 (62.0%) were fe-
male. All patients underwent baseline evaluation for the
presence of human immunodeficiency virus antibody, all
of which produced a negative result. M. avium (50.6%)
and M. intracellulare (47.7%) were the main species de-
tected. Among the 190 patients who underwent drug
susceptibility testing for clarithromycin, the MIC were
8 μg/mL (2 patients), 4 μg/mL (18 patients), 2 μg/mL (69
patients), 1 μg/mL (78 patients), and ≤ 0.5 μg/mL (23 pa-
tients). Upon diagnosis, 81 (34.2%) patients had positive
acid-fast bacilli smear results. The nodular bronchiecta-
tic form was the dominant radiographic pattern (79.8%).
Among the 237 patients, 122 (51.5%) maintained treat-
ment (≥6 months) with all three drugs, 58 (24.5%) main-
tained ethambutol and macrolide, 32 (13.5%) maintained
rifampicin and macrolide, and 25 (10.6%) maintained
macrolide only. Patients who maintained all three agents
tended to be younger (p = 0.003) and had a higher pro-
portion of infections with M. avium (p = 0.018) com-
pared with the other groups of patients (Table 1).
Treatment regimen
After initiation of treatment, patients were followed on
4- to 8-week intervals and sputum specimens were re-
quested to be submitted for acid-fast bacilli smears and
mycobacterial cultures on each visit. Median treatment
duration was 18.6 months (IQR: 16.3–24.3). Azithromy-
cin was prescribed in 183 patients (77.2%) and clarithro-
mycin in 54 (22.8%). For 224 (94.5%) patients,
ethambutol was received for a median of 16.3 (IQR: 7.7–
21.0) months, and 180 (80.4%) maintained the drug for
longer than 6months. For 179 (75.9%) patients, rifampi-
cin was received for a median of 18.2 (IQR: 11.1–23.8)
months, and 154 (86.0%) maintained it for longer than 6
months (Table 2).
Injectable agents were administered to 24 patients
(10.1%) and these included streptomycin (18 patients) and
amikacin (6 patient) (Table 3). A daily regimen was pre-
scribed for 146 patients (61.6%), while 91 (38.4%) started a
three-times-weekly regimen. The median dosage of
ethambutol was 15.4mg/kg for the daily regimen and
22.6mg/kg for the three-times-weekly regimen. Other de-
tailed dosage information is described in (Additional file 1:
Table S1).
Treatment outcomes
Culture conversion was achieved in 190 out of 237
(80.2%) patients after a median of 1.7 (IQR: 0.5–4.7)
months of treatment, and a microbiological cure was
achieved in 129 out of 177 (72.9%) patients who com-
pleted treatment. Of the 60 patients who did not
complete treatment, 58 were still on active treatment,
and 2 were lost to follow-up. The treatment failure rate
was 32.4% (66 patients) among 204 patients with ≥12
months of treatment. Among the 129 patients who
achieved a microbiological cure, 16 patients (12.4%) ex-
perienced recurrence with the same species of MAC
(Table 2).
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Patients who maintained (≥6months) treatment with
either ethambutol, rifampicin or both with macrolide
had a higher probability of culture conversion compared
with maintenance of macrolide only (log-rank p < 0.001)
(Fig. 1). Maintenance of ethambutol and rifampicin with
macrolide (adjusted OR 17.12 with 95% CI 3.93–74.60),
ethambutol and macrolide (adjusted OR 18.06 with 95%
CI 3.67–88.92), and rifampicin and macrolide (adjusted
OR 15.82 with 95% CI 2.38–105.33) showed higher odds
for culture conversion compared with the macrolide
only group. (Table 4).
Predictors for a microbiological cure as well as treat-
ment failure were also evaluated. Maintenance of both
ethambutol and rifampicin (adjusted OR 5.12 with 95%
CI 1.72–15.24), or maintenance of ethambutol (adjusted
OR 5.74 with 95% CI 1.54–21.42) with macrolide was
associated with higher rates of microbiological cure,
while maintenance of rifampicin with macrolide was
not (adjusted OR 2.43 with 95% CI 0.69–8.58)
(Table 5). Compared with the macrolide only group,
odds of treatment failure decreased when ethambutol
and rifampicin were maintained with macrolide (ad-
justed OR 0.09 with 95% CI 0.01–0.53). However,
maintenance of ethambutol (adjusted OR 0.17 with
95% CI 0.03–1.09) or rifampicin (adjusted OR 0.13
with 95% CI 0.01–1.13) with macrolide did not have
this effect (Table 6).
Maintenance of both ethambutol and rifampicin or
one of these with macrolide did not decrease the prob-
ability of recurrence (log-rank p = 0.511).













Age (years) 71 (65–80) 66 (58–75) 66 (56–73) 62 (56–70) 0.003
BMI (kg/m2) 20 (18–22) 21 (18–22) 20 (19–23) 21 (19–22) 0.649
Sex, female 11 (44.0%) 34 (58.6%) 18 (56.3%) 84 (68.9%) 0.086
Smoking history 0.444
Never smoker 12 (48.0%) 35 (60.3%) 21 (65.6%) 82 (67.2%)
Former smoker 9 (36.0%) 14 (24.1%) 5 (15.6%) 21 (17.2%)
Current smoker 1 (4.0%) 3 (5.2%) 1 (3.1%) 2 (1.6%)
Comorbidities
Asthma 2 (8.0%) 0 (0.0%) 1 (3.1%) 2 (1.6%) 0.093
COPD 2 (8.0%) 0 (0.0%) 0 (0.0%) 2 (1.6%) 0.116
History of tuberculosis 11 (44.0%) 17 (29.3%) 7 (21.9%) 26 (21.3%) 0.100
Drug use
Immunomodulatory drugs 2 (8.0%) 0 (0.0%) 0 (0.0%) 6 (4.9%) 0.112
Steroid 1 (4.0%) 1 (1.7%) 1 (3.1%) 3 (2.5%) 0.799
MAC species 0.018
M. avium 9 (36.0%) 24 (41.4%) 12 (37.5%) 75 (61.5%)
M. intracellulare 15 (60.0%) 33 (56.9%) 20 (62.5%) 45 (36.9%)
M. chimaera 1 (4.0%) 1 (1.7%) 0 (0.0%) 1 (0.8%)
M. columbiense 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.8%)
Smear positivity at diagnosis 14 (56.0%) 19 (32.8%) 10 (31.3%) 38 (31.2%) 0.113
Radiographic pattern 0.847
Nodular bronchiectatic 19 (76.0%) 45 (77.6%) 25 (78.1%) 100 (82.0%)
Upper lobe cavitary 6 (24.0%) 13 (22.4%) 7 (21.9%) 22 (18.0%)
Pulmonary function tests
FVC (% predicted) 79 (63–86) 88 (75–97) 90 (74–96) 89 (77–99) 0.086
FEV1 (% predicted) 92 (64–99) 94 (79–104) 90 (80–108) 95 (83–109) 0.582
FEV1/FVC (%) 80 (64–89) 78 (72–83) 79 (70–87) 77 (71–84) 0.928
Values are presented as number (percentage) or median (interquartile range)
Abbreviations: BMI body mass index, COPD chronic obstructive pulmonary disease, MAC Mycobacterium avium complex, FVC forced vital capacity, FEV1 forced
expiratory volume in 1 s
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Acquisition of macrolide resistance
Drug susceptibility testing was repeated for 47 of 66 pa-
tients for whom treatment had failed, and for 12 of 16
patients in whom MAC-PD recurred. Macrolide resist-
ance (MIC ≥32 μg/mL) was acquired by five patients
who experienced treatment failure but these did not in-
clude any with recurrence of MAC-PD. The patients
who acquired macrolide resistance included three males
and two females, with a median age of 59 (IQR: 58–59).
M. intracellulare was the dominant species (four pa-
tients), and an upper lobe cavitary pattern (three pa-
tients) and positive smear results at the initiation of
treatment (three patients) were also common. None
could maintain the three-drug regimen: two maintained
macrolide only, two maintained macrolide with etham-
butol, and one maintained macrolide with rifampicin.
Common causes for omitting or stopping medication in-
cluded decreased visual acuity (four patients), drug-drug
interactions (two patients), and severe nausea (two pa-
tients). Detailed information about each patient is pro-
vided in (Additional file 1: Table S2).
Adverse events
During treatment, 116 (49.0%) patients experienced ad-
verse events. Deterioration of visual acuity was the most
common event reported (31.6%). Other events included
elevated hepatic transaminase (5.9%), general weakness
(5.5%), anorexia (5.1%), nausea (4.6%), rash (4.2%), and
worsened hearing loss (3.4%).
Table 2 Treatment regimen and outcomes of 237 patients with
Mycobacterium avium complex lung disease
Categories Variables Values
Drug use Macrolide 237 (100.0%)
Duration, months 18.6 (16.3–24.3)
Ethambutol 224 (94.5%)
Maintenance (≥6 months) 180 (80.4%)
Duration, for patients with
maintenance, months
18.0 (12.1–22.0)




Maintenance (≥6 months) 154 (86.0%)






Outcomes Culture conversiona 190/237 (80.2%)
Microbiological cureb 129/177 (72.9%)
Treatment failurec 66/204 (32.4%)
Recurrenced 16/129 (12.4%)
Values are presented as number (percentage) or median (interquartile range)
aAt least three consecutive negative results for sputum culture after the start
of treatment. The first day of a negative result was considered the date of
culture conversion
bMaintenance of negative culture conversion until the end of treatment.
Assessed among patients who stopped taking antibiotics
cRe-emergence of multiple positive cultures or persistence with the causative
species from respiratory samples after ≥12 months of antimycobacterial
treatment, while the patient is still on treatment. Assessed among patients
with ≥12 months of antimycobacterial treatment
dThe re-emergence of at least 2 positive cultures with the same species from
sputum after cessation of antimycobacterial treatment. Assessed among
patients with microbiological cure
Table 3 Detailed description of treatment regimens prescribed
in 237 patients
Treatment regimens Values
Macrolide + Ethambutol + Rifampicin 131 (55.3%)
Macrolide + Ethambutol 43 (18.1%)
Macrolide + Ethambutol + Rifampicin
+ Clofazimine
11 (4.6%)
Macrolide + Ethambutol + Rifampicin
+ Injection drug
10 (4.2%)
Macrolide + Ethambutol + Rifampicin
+ Quinolone
7 (3.0%)
Macrolide + Ethambutol + Clofazimine 6 (2.5%)
Macrolide + Rifampicin 6 (2.5%)
Macrolide 4 (1.7%)
Macrolide + Ethambutol + Injection drug 3 (1.3%)
Macrolide + Rifampicin + Injection drug 2 (0.8%)
Macrolide + Ethambutol + Rifampicin
+ Quinolone + Injection drug
2 (0.8%)
Macrolide + Rifampicin + Clofazimine 1 (0.4%)
Macrolide + Ethambutol + Clofazimine
+ Quinolone
1 (0.4%)
Macrolide + Ethambutol + Clofazimine
+ Injection drug
1 (0.4%)
Macrolide + Ethambutol + Quinolone
+ Injection drug
1 (0.4%)
Macrolide + Ethambutol + Rifampicin
+ Injection drug/Inhaled amikacin
1 (0.4%)
Macrolide + Ethambutol + Rifampicin
+ Quinolone + Inhaled amikacin
1 (0.4%)
Macrolide + Ethambutol + Rifampicin
+ Cycloserine + Pyrazinamide
1 (0.4%)
Macrolide + Ethambutol + Rifampicin
+ Amoxicillin/clavulanate
1 (0.4%)
Macrolide + Ethambutol + Rifampicin
+ Clofazimine + Injection drug/Inhaled
amikacin
1 (0.4%)
Macrolide + Ethambutol + Rifampicin
+ Clofazimine + Quinolone + Injection
drug
1 (0.4%)
Macrolide + Ethambutol + Rifampicin
+ Quinolone + Amoxicillin/clavulanate
1 (0.4%)
Macrolide + Ethambutol + Rifampicin
+ Quinolone + Injection drug/Inhaled
amikacin
1 (0.4%)
Values are presented as numbers (%). Includes drugs used after the diagnosis
of Mycobacterium avium complex lung disease
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Among the 224 patients who received ethambutol, 92
(41.1%) of them stopped taking this drug because of
adverse events including deteriorated visual acuity (72
patients), anorexia (8 patients), rash (8 patients), and
hepatic dysfunction (8 patients). Early cessation (< 6
months) of ethambutol was observed in 44 patients
(19.6%), mainly because of deteriorated visual acuity (35
patients), rash (6 patients), and anorexia (5 patients). Of
the 179 patients who received rifampicin, 47 (26.3%) of
them had to stop administration due to general weak-
ness (10 patients), nausea (9 patients), anorexia (8
patients), hepatic dysfunction (7 patients), and abdom-
inal pain (6 patients). Early cessation (< 6 months) of
rifampicin was observed in 25 patients (14.0%), mostly
as a result of anorexia (6 patients), general weakness (6
patients), nausea (5 patients), hepatic dysfunction (5 pa-
tients), and rash (4 patients). Patient characteristics
regarding the usage of ethambutol and rifampicin and
the reasons for withholding these drugs are provided in
(Additional file 1: Table S3).
Discussion
In this study, among the 237 patients who started treat-
ment for MAC-PD, 190 (80.2%) reached culture conver-
sion, and 129 of the 177 patients who completed
treatment (72.9%) achieved microbiological cure. Of the
204 patients who underwent ≥12months of treatment,
66 (32.4%) were classified as having treatment failure.
Sixteen of the 129 patients with microbiological cure
(12.4%) experienced recurrence of MAC-PD. Most pa-
tients started out using macrolide (100.0%), ethambutol
Fig. 1 Probability of culture conversion according to the
maintenance (≥6 months) of ethambutol and rifampicin.
Abbreviations: M, macrolide; E, ethambutol; R, rifampicin
Table 4 Predictors for culture conversion among treated Mycobacterium avium complex pulmonary disease patients
Variables Unadjusted OR (95% CI) P Adjusted OR (95% CI) P
Age (years) 0.95 (0.92–0.98) 0.003 1.01 (0.96–1.06) 0.680
BMI (kg/m2) 1.23 (1.06–1.41) 0.005 1.21 (1.02–1.44) 0.031
Sex, female 2.72 (1.42–5.23) 0.003 1.43 (0.55–3.74) 0.468
History of tuberculosis 0.53 (0.27–1.05) 0.070
MAC species
M. avium Reference Reference
M. intracellulare 0.26 (0.13–0.53) < 0.001 0.29 (0.10–0.84) 0.022
Smear positivity at diagnosis 0.18 (0.09–0.37) < 0.001 0.10 (0.04–0.29) < 0.001
Radiographic pattern
Nodular bronchiectatic form Reference Reference
Upper lobe cavitary form 0.45 (0.22–0.92) 0.029 0.39 (0.13–1.12) 0.079
Pulmonary function tests
FVC (% predicted) 1.01 (0.99–1.03) 0.293
FEV1 (% predicted) 1.00 (0.98–1.01) 0.742
FEV1/FVC (%) 0.97 (0.94–1.01) 0.101
Maintenance of antibiotics (≥6mo)
M only Reference Reference
M + E 9.68 (3.28–28.58) < 0.001 18.06 (3.67–88.92) < 0.001
M + R 4.54 (1.48–13.96) 0.008 15.82 (2.38–105.33) 0.004
M + E + R 14.91 (5.49–40.47) < 0.001 17.12 (3.93–74.60) < 0.001
Culture conversion was defined as at least three consecutive negative results for sputum culture the start of treatment
Abbreviations: OR odds ratio, CI confidence interval, BMI body mass index, MAC Mycobacterium avium complex, FVC forced vital capacity, FEV1 forced expiratory
volume in 1 s, M macrolide, E ethambutol, R rifampicin
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(94.5%), and rifampicin (75.9%) as a multidrug combin-
ation treatment. Maintenance (≥6 months) of both eth-
ambutol and rifampicin with macrolide was associated
with the most favorable outcomes: higher odds of cul-
ture conversion as well as microbiological cure, and
lower odds of treatment failure.
Treatment outcomes in this study were comparable
with those of previous studies. In two retrospective ana-
lyses and one randomized controlled trial, rates of cul-
ture conversion for MAC-PD using a macrolide-
containing regimen was reported as 40–95% [14, 15, 17].
In addition, two meta-analyses reported culture conver-
sion rates of 55–57% without recurrence [6, 8].
Our study showed that maintenance of ethambutol
was more strongly associated with microbiological cure
than rifampicin. Ethambutol inhibits arabinosyltransfer-
ase and blocks arabinogalactan synthesis, which forms
part of the mycobacterial wall [18–20]. With such mech-
anism, the synergistic effect of ethambutol is expected
when used with other antimycobacterial agents. The ef-
fects of ethambutol on MAC was reported in animal
studies, which reduced MAC growth in the blood, liver,
and spleen [21]. In a human study, ethambutol reduced
the mycobacteremia level in AIDS patients [22]. Another
study reported that more than 5months of ethambutol
use was associated with improvement in MAC culture
[23]; however, that study used the reduction in colony
count as an outcome rather than the strict criteria of
culture conversion or treatment success [16, 24]. Given
the favorable effects of maintenance of ethambutol in
our study, cessation of ethambutol early during the
course of treatment based on uncertain adverse events
should be avoided [25, 26].
Although our study raised concerns regarding the ef-
fectiveness of rifampicin and macrolide without etham-
butol in terms of microbiological cure, the importance
of a rifamycin in the treatment of MAC was noted in
earlier studies: rifabutin was effective in reducing myco-
bacterial titers among AIDS patients with disseminated
MAC infection [27], and synergistic effects of rifampicin
and ethambutol on MAC were shown in vitro in liquid
media [28]. In addition, maintenance of a single drug (ri-
fampicin or ethambutol) supplemented with macrolide
could result in the emergence of clarithromycin resist-
ance, as was shown in the present study. However, the
effect of rifampicin has been questioned in other studies:
in an open-label randomized controlled trial comparing
a two-drug regimen (clarithromycin, ethambutol) with a
three-drug regimen (clarithromycin, ethambutol, and ri-
fampicin), the 12-month sputum-negative conversion
Table 5 Predictors for microbiological cure among patients who completed treatment
Variables Unadjusted OR (95% CI) P Adjusted OR (95% CI) P
Age (years) 0.96 (0.93–1.00) 0.029 0.99 (0.96–1.03) 0.615
BMI (kg/m2) 1.13 (0.97–1.32) 0.112
Sex, female 1.50 (0.76–2.96) 0.238
History of tuberculosis 0.51 (0.24–1.04) 0.065
MAC species
M. avium Reference Reference
M. intracellulare 0.32 (0.16–0.64) 0.001 0.33 (0.15–0.73) 0.006
Smear positivity at diagnosis 0.39 (0.19–0.79) 0.008 0.46 (0.21–1.02) 0.056
Radiographic pattern
Nodular bronchiectatic form Reference
Upper lobe cavitary form 0.87 (0.38–1.98) 0.738
Pulmonary function tests
FVC (% predicted) 1.01 (0.99–1.03) 0.229
FEV1 (% predicted) 1.00 (0.99–1.02) 0.801
FEV1/FVC (%) 0.97 (0.94–1.01) 0.126
Maintenance of antibiotics (≥6mo)
M only Reference Reference
M + E 7.58 (2.19–26.26) 0.001 5.74 (1.54–21.42) 0.009
M + R 2.98 (0.93–9.57) 0.067 2.43 (0.69–8.58) 0.168
M + E + R 7.58 (2.77–20.79) < 0.001 5.12 (1.72–15.24) 0.003
Microbiological cure was defined as maintenance of negative culture conversion at the end of treatment. Assessed among 177 patients who completed treatment
Abbreviations: OR odds ratio, BMI body mass index, MAC Mycobacterium avium complex, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, M
macrolide, E ethambutol, R rifampicin
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rates between the two groups were equivalent [17]. An-
other study demonstrated a good treatment success rate
among MAC-PD patients treated with a three-drug regi-
men of macrolide, ethambutol, and clofazimine without
rifampicin [29]. The weaker effect of rifampicin for the
treatment of MAC-PD could be explained based on a
lowered serum level of macrolide through induction of
cytochrome p450 by rifampicin, although one previous
report suggested that the serum concentration does not
affect treatment outcomes [30, 31]. It can also be ex-
plained that rifampicin has antimycobacterial activity by
binding to the β subunit of RNA polymerase, thereby
inhibiting RNA synthesis [32]. In slowly growing myco-
bacteria such as MAC species, such a mechanism may
result in a bacteriostatic effect rather than a bactericidal
effect [33]. In fact, clinical significance of synergistic ac-
tivity of rifampicin and ethambutol against slow-growing
NTM was doubted in a previous study [34].
Although maintenance of ethambutol appears to be
very important in the treatment of MAC-PD, the possi-
bility of optic neuropathy should be considered with
prolonged use of ethambutol. Among patients taking
ethambutol for pulmonary TB, ethambutol-induced
optic neuropathy develops in 1–2% in a dose-dependent
manner [35]. In addition, about 0.2–0.3% of patients
may experience irreversible visual function loss. In our
study, about one-third of patients experienced worsened
visual acuity and it was major cause of earlier cessation
of ethambutol. Given its effectiveness as well as risk of
optic neuropathy, the best strategy could be long-term
use of ethambutol with active surveillance of visual acu-
ity and rapid objective assessment in the setting of sub-
jective deterioration.
This study had some limitations. First, it was a retro-
spective study based on a single center. Patients receiv-
ing treatment at the time of data retrieval could not be
included in several of the analyses. Potential confounders
that were not considered in our study (e.g. concomitant
medications or the radiographic extent of the disease)
may exist between the study groups. Future well-
designed, randomized controlled clinical trials will be
necessary to fully understand the roles of ethambutol
and rifampicin in MAC-PD. Second, the adverse events
of medication were self-reported, and the visual acuity
loss was not evaluated objectively. This may have led to
a high prevalence of ethambutol-induced ocular toxicity.
However, there are currently no standardized protocols
for detecting ethambutol-induced ocular toxicity, and
Table 6 Predictors for treatment failure among patients with ≥12 months of antimycobacterial treatment
Variables Unadjusted OR (95% CI) P Adjusted OR (95% CI) P
Age (years) 1.03 (1.00–1.06) 0.029 0.99 (0.93–1.04) 0.628
BMI (kg/m2) 0.86 (0.75–0.99) 0.037 0.88 (0.72–1.07) 0.194
Sex, female 0.55 (0.30–1.00) 0.048 0.76 (0.27–2.14) 0.602
History of tuberculosis 1.70 (0.90–3.23) 0.103
MAC species
M. avium Reference Reference
M. intracellulare 2.91 (1.58–5.39) 0.001 1.46 (0.51–4.17) 0.484
Smear positivity at diagnosis 3.32 (1.79–6.16) < 0.001 7.42 (2.68–20.56) < 0.001
Radiographic pattern
Nodular bronchiectatic form Reference
Upper lobe cavitary form 1.78 (0.89–3.58) 0.105
Pulmonary function tests
FVC (% predicted) 0.98 (0.97–1.00) 0.093
FEV1 (% predicted) 1.00 (0.98–1.01) 0.760
FEV1/FVC (%) 1.03 (1.00–1.07) 0.043 1.04 (0.99–1.09) 0.099
Maintenance of antibiotics (≥6mo)
M only Reference Reference
M + E 0.28 (0.09–0.82) 0.021 0.17 (0.03–1.09) 0.061
M + R 0.57 (0.18–1.82) 0.344 0.13 (0.01–1.13) 0.064
M + E + R 0.19 (0.07–0.50) 0.001 0.09 (0.01–0.53) 0.008
Treatment failure was defined as re-emergence of multiple positive cultures or persistence with the causative species from respiratory samples after ≥12 months
of antimycobacterial treatment, while the patient is still on treatment. Assessed among 204 patients with ≥12 months of antimycobacterial treatment
Abbreviations: OR odds ratio, BMI body mass index, MAC Mycobacterium avium complex, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, M
macrolide, E ethambutol, R rifampicin
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self-reported visual loss is a reliable means to determine
optic neuritis from ethambutol [36]. Third, re-infection
and relapse of MAC could not be differentiated between
among patients with recurrence because genetic com-
parisons of the causative strains were not performed in
our study. The lack of such analyses might have resulted
in the insignificant associations between maintenance of
ethambutol or rifampicin and the risk of recurrence after
microbiological cure.
Conclusions
Maintenance (≥6 months) of ethambutol and rifampicin
treatment with macrolide was associated with the most
favorable treatment outcomes among patients with
MAC-PD. Given the impact of ethambutol on microbio-
logical cure, clinicians should maintain ethambutol un-
less definite and serious adverse events develop from
ethambutol treatment.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12890-019-0982-8.
Additional file 1: Table S1. Detailed dosage information about the
antimycobacterial agents used in the treatment of Mycobacterium avium
complex lung disease. Table S2. Detailed description of 5 patients who
developed clarithromycin resistance during treatment failure. Table S3.
Patient characteristics according to the use of ethambutol and rifampicin.
Abbreviations
AIDS: Acquired immune deficiency syndrome; CI: Confidence interval;
IQR: Interquartile range; MAC: Mycobacterium avium complex; MIC: Minimal
inhibitory concentration; NTM: Nontuberculous mycobacteria; OR: Odds ratio;
PD: Pulmonary disease
Acknowledgements
We thank the Medical Research Collaborating Centre (Seoul National
University Hospital, Seoul, South Korea) for the statistical analyses and
Alexander Pishief, LLB, BBmedSc, from Edanz Group (www.edanzediting.com/
ac) for English editing a draft of this manuscript.
Authors’ contributions
HJK, JSL, NK, SKH and JJY contributed to the conception and design of the
study. HJK, JSL and JJY contributed to the acquisition of the data. HJK, JC,
and CHL contributed to the analysis of the data. HJK and JJY contributed to
the interpretation of the data. HJK drafted the article. HJK and JJY critically
revised the article for important intellectual content. HJK, JSL, NK, JC, CHL,
SKH and JJY had access to the final version of the manuscript and approved
the version to be published. HJK, JSL, NK, JC, CHL, SKH and JJY made
significant contributions to the work. JJY had full access to all of the data in
the study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Funding
None.
Availability of data and materials
Data are available from the corresponding author upon a reasonable
request.
Ethics approval and consent to participate
The study was conducted in accordance with the amended Declaration of
Helsinki and was approved by the institutional review board of Seoul
National University Hospital (protocol number: H-1705-017-851). Informed
consent was waived because of the retrospective design of the study, and




The authors declare that they have no competing interests.
Author details
1Division of Pulmonary and Critical Care Medicine, Department of Internal
Medicine, Seoul National University Hospital, 101 Daehak-ro Jongno-gu,
Seoul 03080, Republic of Korea. 2Division of Pulmonary Medicine,
Department of Internal Medicine, Mediplex Sejong Hospital, 20
Gyeyangmunhwa-ro Gyeyang-gu, Incheon 21080, Republic of Korea.
Received: 12 October 2018 Accepted: 31 October 2019
References
1. Shiau MY, Lee MS, Huang TL, Tsai JN, Chang YH. Mycobacterial prevalence
and antibiotic resistance frequency trends in Taiwan of mycobacterial
clinical isolates from 2002 to 2014. Medicine (Baltimore). 2016;95(12):e2942.
2. McShane PJ, Glassroth J. Pulmonary disease due to nontuberculous
mycobacteria: current state and new insights. Chest. 2015;148(6):1517–27.
3. Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of
pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003. Thorax.
2007;62(8):661–6.
4. Daley CL. Mycobacterium avium complex disease. Microbiol Spectr. 2017;
5(2):1–36.
5. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al.
An official ATS/IDSA statement: diagnosis, treatment, and prevention of
nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;
175(4):367–416.
6. Kwak N, Park J, Kim E, Lee CH, Han SK, Yim JJ. Treatment outcomes of
Mycobacterium avium complex lung disease: a systematic review and
meta-analysis. Clin Infect Dis. 2017;65(7):1077–84.
7. Shafran SD, Singer J, Zarowny DP, Phillips P, Salit I, Walmsley SL, et al. A
comparison of two regimens for the treatment of Mycobacterium avium
complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin
versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV
Trials Network Protocol 010 Study Group. N Engl J Med. 1996;335(6):377–83.
8. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary
disease in patients without hiv infection. Chest. 2004;126(2):566–81.
9. Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF,
et al. British Thoracic Society guidelines for the management of non-
tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;
72(Suppl 2):ii1–ii64.
10. Kim SJ, Yoon SH, Choi SM, Lee J, Lee CH, Han SK, et al. Characteristics
associated with progression in patients with of nontuberculous
mycobacterial lung disease: a prospective cohort study. BMC Pulm Med.
2017;17(1):5.
11. Lee AR, Lee J, Choi SM, Seong MW, Kim SA, Kim M, et al. Phenotypic,
immunologic, and clinical characteristics of patients with nontuberculous
mycobacterial lung disease in Korea. BMC Infect Dis. 2013;13:558.
12. Clinical and Laboratory Standards Institute. Interpretive criteria for
identification of bacteria and fungi by DNA target sequencing; approved
guideline. CLSI document MM18-A. Wayne: Clinical and Laboratory
Standards Institute; 2008.
13. Kim HS, Lee KS, Koh WJ, Jeon K, Lee EJ, Kang H, et al. Serial CT findings of
Mycobacterium massiliense pulmonary disease compared with
Mycobacterium abscessus disease after treatment with antibiotic therapy.
Radiology. 2012;263(1):260–70.
14. Jarand J, Davis JP, Cowie RL, Field SK, Fisher DA. Long-term follow-up of
Mycobacterium avium complex lung disease in patients treated with
regimens including clofazimine and/or rifampin. Chest. 2016;149(5):1285–93.
15. Jeong BH, Jeon K, Park HY, Kim SY, Lee KS, Huh HJ, et al. Intermittent
antibiotic therapy for nodular bronchiectatic Mycobacterium avium
complex lung disease. Am J Respir Crit Care Med. 2015;191(1):96–103.
Kim et al. BMC Pulmonary Medicine          (2019) 19:212 Page 9 of 10
16. van Ingen J, Aksamit T, Andrejak C, Bottger EC, Cambau E, Daley CL, et al.
Treatment outcome definitions in nontuberculous mycobacterial pulmonary
disease: an NTM-NET consensus statement. Eur Respir J. 2018;51(3):1800170.
17. Miwa S, Shirai M, Toyoshima M, Shirai T, Yasuda K, Yokomura K, et al. Efficacy of
clarithromycin and ethambutol for Mycobacterium avium complex pulmonary
disease. A preliminary study. Ann Am Thorac Soc. 2014;11(1):23–9.
18. Deng L, Mikusova K, Robuck KG, Scherman M, Brennan PJ, McNeil MR.
Recognition of multiple effects of ethambutol on metabolism of mycobacterial
cell envelope. Antimicrob Agents Chemother. 1995;39(3):694–701.
19. Takayama K, Kilburn JO. Inhibition of synthesis of arabinogalactan by
ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother.
1989;33(9):1493–9.
20. Belanger AE, Besra GS, Ford ME, Mikusova K, Belisle JT, Brennan PJ, et al. The
embAB genes of Mycobacterium avium encode an arabinosyl transferase involved
in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug
ethambutol. Proc Natl Acad Sci U S A. 1996;93(21):11919–24.
21. Bermudez LE, Kolonoski P, Petrofsky M, Wu M, Inderlied CB, Young LS.
Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to
macrolide-containing regimens for treatment of Mycobacterium avium
disease. J Infect Dis. 2003;187(12):1977–80.
22. Kemper CA, Havlir D, Haghighat D, Dube M, Bartok AE, Sison JP, et al. The
individual microbiologic effect of three antimycobacterial agents,
clofazimine, ethambutol, and rifampin, on Mycobacterium avium complex
bacteremia in patients with AIDS. J Infect Dis. 1994;170(1):157–64.
23. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL, et al. Factors
related to response to intermittent treatment of Mycobacterium avium
complex lung disease. Am J Respir Crit Care Med. 2006;173(11):1283–9.
24. Griffith DE, Brown BA, Murphy DT, Girard WM, Couch L, Wallace RJ Jr. Initial
(6-month) results of three-times-weekly azithromycin in treatment regimens
for Mycobacterium avium complex lung disease in human
immunodeficiency virus-negative patients. J Infect Dis. 1998;178(1):121–6.
25. Wallace RJ Jr, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW,
et al. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium
avium complex lung disease. Chest. 2014;146(2):276–82.
26. Koh WJ, Jeong BH, Jeon K, Lee NY, Lee KS, Woo SY, et al. Clinical significance
of the differentiation between Mycobacterium avium and Mycobacterium
intracellulare in M avium complex lung disease. Chest. 2012;142(6):1482–8.
27. Sullam PM, Gordin FM, Wynne BA. Efficacy of rifabutin in the treatment of
disseminated infection due to Mycobacterium avium complex. The
Rifabutin Treatment Group. Clin Infect Dis. 1994;19(1):84–6.
28. Hoffner SE, Svenson SB, Kallenius G. Synergistic effects of antimycobacterial
drug combinations on Mycobacterium avium complex determined
radiometrically in liquid medium. Eur J Clin Microbiol. 1987;6(5):530–5.
29. Field SK, Cowie RL. Treatment of Mycobacterium avium-intracellulare
complex lung disease with a macrolide, ethambutol, and clofazimine. Chest.
2003;124(4):1482–6.
30. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum
levels of clarithromycin in patients treated with multidrug regimens
including rifampin or rifabutin for Mycobacterium avium-M. intracellulare
infection. J Infect Dis. 1995;171(3):747–50.
31. Koh WJ, Jeong BH, Jeon K, Lee SY, Shin SJ. Therapeutic drug monitoring in
the treatment of Mycobacterium avium complex lung disease. Am J Respir
Crit Care Med. 2012;186(8):797–802.
32. Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis.
1983;5(Suppl 3):S407–11.
33. Prince DS, Peterson DD, Steiner RM, Gottlieb JE, Scott R, Israel HL, et al.
Infection with Mycobacterium avium complex in patients without
predisposing conditions. N Engl J Med. 1989;321(13):863–8.
34. van Ingen J, Hoefsloot W, Mouton JW, Boeree MJ, van Soolingen D.
Synergistic activity of rifampicin and ethambutol against slow-growing
nontuberculous mycobacteria is currently of questionable clinical
significance. Int J Antimicrob Agents. 2013;42(1):80–2.
35. Chamberlain PD, Sadaka A, Berry S, Lee AG. Ethambutol optic neuropathy.
Curr Opin Ophthalmol. 2017;28(6):545–51.
36. Kim KL, Park SP. Visual function test for early detection of ethambutol
induced ocular toxicity at the subclinical level. Cutan Ocul Toxicol. 2016;
35(3):228–32.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Kim et al. BMC Pulmonary Medicine          (2019) 19:212 Page 10 of 10
